Drug
Roscovitine clinical trials
Also written Seliciclib and CYC202.
- studies test it
- 7
- open now
- 0
- in phase 3
- 0
- first study started
- 2006
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2009 (2)
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2009 | 2 |
| 2012 | 1 |
| 2014 | 1 |
| 2016 | 1 |
| 2018 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 4
Cyclacel Pharmaceuticals, Inc. (2) · Cedars-Sinai Medical Center (1) · Alcon Research (1) · University Hospital, Brest (1) · Shlomo Melmed, MD (1) · M.D. Anderson Cancer Center (1)
Often tested with
Tested in the same studies.
Sapacitabine (1) · Liposomal doxorubicin (1) · Doxorubicin (1)
Related medicines
As reviewed, each with the page that says it.
- One of Protein Kinase Inhibitors source
Studies
Open first, then newest update. How each study uses Roscovitine is read from its arms, and is right about nine times in ten.
Testing it · 7
- Multicenter Study of Seliciclib (R-roscovitine) for Cushing DiseaseCompletedPhase 2Cedars-Sinai Medical CenterNCT03774446Written as Seliciclib
- Evaluation of (R)-Roscovitine Safety and Effects in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR MutationTerminatedPhase 2University Hospital, BrestNCT02649751Written as Roscovitine
- A Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid TumorsCompletedPhase 1Cyclacel Pharmaceuticals, Inc.NCT00999401Written as sapacitabine and seliciclib
- Efficacy Study of Oral Seliciclib to Treat Non-Small Cell Lung CancerTerminatedPhase 2Cyclacel Pharmaceuticals, Inc.NCT00372073Written as seliciclib
- Treatment of Cushing's Disease With R-roscovitineTerminatedPhase 2Shlomo Melmed, MDNCT02160730Written as R-roscovitine
- Safety and Intraocular Pressure (IOP)-Lowering Efficacy of AL-39256 in Patients With Open-Angle Glaucoma or Ocular HypertensionCompletedPhase 2Alcon ResearchNCT00761709Written as AL-39256 Ophthalmic Suspension, 1%
- Maximum Tolerated Dose (MTD) of Liposomal Doxorubicin in Combination With Seliciclib for Patients With Metastatic Triple Negative Breast Cancer (TNBC)WithdrawnPhase 1M.D. Anderson Cancer CenterNCT01333423Written as Seliciclib
Codes
What other systems call Roscovitine · ClinicalTrials.gg INT006743
- MeSH (NLM) D000077546RoscovitineConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 0ES1C2KQ94SELICICLIBConfirmed FDA, NLM
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000077546 | Roscovitine | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 0ES1C2KQ94 | SELICICLIB | Confirmed FDA, NLM |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.